TetraPhase Pharmaceuticals Announces Positive Phase 2 Data for Eravacycline (TP-434) in Patients With Complicated Intra-Abdominal Infections (cIAIs)

Published: Sep 12, 2012

SAN FRANCISCO--(BUSINESS WIRE)--Tetraphase Pharmaceuticals, Inc., a clinical-stage life science company developing novel antibiotics effective against antibiotic-resistant bacteria, presented new, positive Phase 2 clinical data on its lead drug candidate, eravacycline (TP-434), on September 11, 2012, at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco, CA. The results of the study show that eravacycline was highly active against drug-resistant bacterial pathogens, demonstrating infection cure rates similar to that of ertapenem (the comparator drug used in the trial) for the treatment of cIAI and a strong safety profile (with low rates of gastrointestinal side effects). These data support Phase 3 development of eravacycline for the treatment of serious infections, including those caused by resistant gram-negative pathogens.

Back to news